These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35795092)

  • 1. An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition.
    Sun Y; Zhang Z; Zhang C; Zhang N; Wang P; Chu Y; Chard Dunmall LS; Lemoine NR; Wang Y
    Mol Ther Oncolytics; 2022 Sep; 26():105-119. PubMed ID: 35795092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.
    Marelli G; Chard Dunmall LS; Yuan M; Di Gioia C; Miao J; Cheng Z; Zhang Z; Liu P; Ahmed J; Gangeswaran R; Lemoine N; Wang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
    Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors.
    Wei M; Zuo S; Chen Z; Qian P; Zhang Y; Kong L; Gao H; Wei J; Dong J
    Front Immunol; 2022; 13():1017574. PubMed ID: 36451817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment.
    Azar F; Deforges J; Demeusoit C; Kleinpeter P; Remy C; Silvestre N; Foloppe J; Fend L; Spring-Giusti C; Quéméneur E; Marchand JB
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.
    Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L
    Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models.
    Ye J; Chen L; Waltermire J; Zhao J; Ren J; Guo Z; Bartlett DL; Liu Z
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps.
    Kober C; Rohn S; Weibel S; Geissinger U; Chen NG; Szalay AA
    J Transl Med; 2015 Jul; 13():216. PubMed ID: 26149494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 16. Ki67-targeted oncolytic adenovirus expressing IL-15 improves intratumoral T cell infiltration and PD-L1 expression in glioblastoma.
    Zhang Q; Zhang J; Tian Y; Wang J; Jin G; Liu F
    Virology; 2023 Oct; 587():109885. PubMed ID: 37738842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.
    Ferguson MS; Chard Dunmall LS; Gangeswaran R; Marelli G; Tysome JR; Burns E; Whitehead MA; Aksoy E; Alusi G; Hiley C; Ahmed J; Vanhaesebroeck B; Lemoine NR; Wang Y
    Mol Ther; 2020 May; 28(5):1263-1275. PubMed ID: 32145202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
    Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma.
    Martikainen M; Ramachandran M; Lugano R; Ma J; Martikainen MM; Dimberg A; Yu D; Merits A; Essand M
    Mol Ther Oncolytics; 2021 Jun; 21():37-46. PubMed ID: 33869741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment.
    Yoo SY; Badrinath N; Jeong SN; Woo HY; Heo J
    Vaccines (Basel); 2020 Jun; 8(2):. PubMed ID: 32575351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.